A Study of Single Dose of LP-003 in Adolescent Subjects

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

September 30, 2026

Conditions

Chronic Spontaneous Urticaria (CSU)Seasonal Allergic Rhinitis (SAR)

Interventions

BIOLOGICAL

LP-003 Dose 1 (Single)

A single dose of LP-003 (400 mg/dose) was SC

BIOLOGICAL

LP-003 Dose 2 (Single)

A single dose of LP-003 (600 mg/dose) was SC